Intestinal Cell News

Intestinal Cell News is an online resource that curates the latest research using intestinal cells.

US FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

March 6, 2026

[Pfizer Inc. ] Pfizer Inc., announced that the US FDA has granted full approval to BRAFTOVI^® in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation based on results from the global Phase III BREAKWATER trial.

Five Global Teams Awarded $125 Million to Take on the Toughest Challenges at the Frontiers of Cancer Science

March 6, 2026

[Cancer Grand Challenges (Business Wire)] Cancer Grand Challenges, a global initiative co-founded by the National Cancer Institute in the US and Cancer Research UK, announced a major $125m commitment to propel cancer research into uncharted territory.

Villification of the Intestinal Epithelium Is Driven by Foxl1 through Activation of PDGFRα and BMPs

March 6, 2026

[Nature Communications] Investigators set out to determine the molecular targets and pathways controlled by Foxl1 during intestinal villification

Systematic Analysis of Functional Genetic and Epigenetic Variants in Colorectal Cancer

March 6, 2026

[Science Advances] Scientists adapted and applied two high-throughput techniques, SNP-STARR-seq and Methyl-STARR-seq, to systematically evaluate the influence of 30,790 noncoding SNPs and more than 134,000 CpG sites on enhancer activity in primary and metastatic CRC cells.

PKM2 Lactylation Promotes Colorectal Cancer Vasculogenic Mimicry and Bevacizumab Resistance by Facilitating FOSL1 Super-Enhancer Formation

March 6, 2026

[Cancer Research] Researchers revealed lactylation as a metabolic switch linking cancer glycolytic reprogramming to transcriptional rewiring and proposes targeting PKM2 lactylation to enhance the anti-tumor activity of bevacizumab in colorectal cancer.

P53 and Fatty Acids Collaborate to Trigger Ferroptosis via the FBXO2-FABP5 Axis in Colorectal Cancer

March 6, 2026

[Redox Biology] The authors revealed that p53 induces ferroptosis in the presence of abundant polyunsaturated fatty acids (PUFAs). They uncovered that the availability of PUFAs is crucial for p53 to exert a pro-ferroptotic function in colorectal cancer.

Glucose Metabolism Sustains Aberrant STAT3 Signaling in Colorectal Cancer through Glycosylated Local Signaling Factor

March 6, 2026

[Science Signaling] Investigators demonstrated that glucose sustained STAT3 activation independently of cytokine availability. Their findings showed how glucose metabolism supports sustained STAT3 activation in colorectal cancer.

Claudin18.2 Promote Gastric Cancer Proliferation by Activating MCM2/5

March 6, 2026

[Scientific Reports] Researchers found that knockdown of claudin18.2 (CLDN18.2) inhibited tumor growth in vivo and in vitro. Additionally, CLDN18.2 knockdown down-regulated minichromosome maintenance (MCM) proteins and decreased phosphorylation of ERK, CDK, and MCM2 in gastric cancer cells.

The TAAR1 Antagonist EPPTB Ameliorates Colitis via Serotonin Inhibition

March 6, 2026

[Biochemistry and Biophysics Reports] Scientists evaluated the effects of the TAAR1 antagonist EPPTB in a DSS-induced colitis model, focusing on inflammation, barrier function, and serotonin signaling, to explore its therapeutic potential.

Reshaping the Colorectal Cancer Immune Microenvironment: Insights from Single-Cell and Spatial Omics

March 6, 2026

[Cancer Cell International] Investigators synthesize single-cell RNA sequencing and spatial transcriptomic studies of colorectal cancer to characterize cellular heterogeneity and to delineate spatial niche organization and functional crosstalk within the tumor microenvironment.

Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis

February 20, 2026

[Everest Medicines] Everest Medicines announced that China's National Medical Products Administration (NMPA) has approved VELSIPITY^® for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Palmitic Acid Activates C-Myc via Dual Palmitoylation-Dependent Pathways to Promote Colon Cancer

February 20, 2026

[Cell Discovery] Researchers identified palmitic acid as a metabolite cue that activates c-Myc via dual palmitoylation-dependent pathways operating across tumor initiation and progression.

Since 2015, Intestinal Cell News has been a valuable resource for keeping researchers and medical professionals updated on the latest publications, news and events in the field of gastrointestinal cell biology. Our editorial team collects and publishes the most current articles and reviews using stomach, colon, and small and large intestinal cells. We cover topics including the culturing of intestinal cells, intestinal organoids, intestinal cancers, and gastrointestinal conditions such as irritable bowel syndrome and Crohn’s disease.